Conventional oral dosage forms having low bioavailability problems due to their rapid gastric transition from stomach, in case of drugs which are less soluble at alkaline pH of intestine.
Introduction
Generally, oral drug administration has been the prevalent route for drug delivery. Amid the previous two decades, various oral delivery systems have been created to go about as drug reservoirs from which the active substance can be released over a defined period of time at a predetermined and controlled rate. From a pharmacokinetic perspective, the ideal sustained and controlled release dosage form should be comparable with an intravenous infusion, which supplies c consistently the amount of drug expected to keep up consistent plasma levels once the steady state is reached 1 .
Although some significant applications, including oral administration of peptide and protein drugs, can be utilized to prepare colonic drug delivery systems, targeting drugs to the colon by the oral route. More often, drug absorption is unsatisfactory and highly variable among and between people, in spite of phenomenal in vitro release patterns. The explanations behind this are basically physiological and typically influenced by the gastrointestinal (GI) transit of the form, particularly its gastric residence time (GRT), which seems to be one of the significant reasons of the overall transit time variability 2, 3 .
In the course of recent decades, the interest and investigation of devices designed to be retained in the upper part of the GI tract has progressed reliably as far as innovation and decent variety, encompassing a variety of systems and devices for example, floating systems, raft systems, expanding systems, swelling systems, bioadhesive systems and low-density systems.
Stomach explicit (Gastric retention) will provide advantages such as the delivery of drugs with narrow absorption windows in the small intestinal region. Likewise, longer residence time in the stomach could be beneficial for local action in the upper part of the small intestine, for example treatment of peptic ulcer disease 4, 5 . Gastric retention time can be drawn out by different techniques, for example, floating drug delivery system (hydro dynamically balanced system), swelling and expanding systems, polymeric boiadhesive system, modified-shape system, high density system, and other delayed gastric emptying devices. Oral in situ gel forming system also known as stomach specific or raft forming systems have given an appropriate method for providing the controlled drug delivery inside stomach with improved gastro-retention.
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Floating In-situ gel
In situ gel forming systems have been broadly examined, for their capability of producing the sustained and controlled drug delivery. In recent years, research has been completed in detailing in situ gel by means of prevalent routes like oral, nasal, ophthalmic and other routes like vagina. This demonstrated the promising outcome, for the utilization of system as a potential method of producing the controlled drug delivery. This system essentially uses polymers which undergo transformation from solution to gel like consistency, because of progress in their physicochemical properties. This system contains in situ gel forming polymers of synthetic or natural origin, e.g. gellan gum, alginic acid, xyloglucan, chitosan, polycarolactone and so on.
Addition of bicarbonates or carbonates to this system improves floating ability by producing effervescence by releasing carbon dioxide (air generation) will make the gel much lighter and in turn helps to float. Capacity of the gel for prolonged and controlled release may also be enhanced by raising its viscosity with the help of viscosity enhancers 6, 8 . 
Advantages of floating in situ gel
Physical change
By this methodology physical change like swelling or diffusion may happens. In swelling, polymer in the system absorbs water from the surrounding environment and swells to shape a viscous gel. In diffusion, solvent in which the drug and polymer is dispersed or dissolved, diffuse into the surrounding tissues making the precipitation of the polymer to form gel.
Chemical change
Change in chemical environment prompts polymeric cross linking thereby formation of gel 6 .
Change in temperature
Change in temperature prompts change in the solubility of polymer, thereby polymer-polymer interaction takes place to form a macromolecule of hydrophobic nature.
Change in pH
Polymer with anionic groups leads to increase in swelling with increase in the pH, while polymer with cationic groups shows a decrease in the swelling.
Dilution-sensitive
A polymer that undergoes phase transition in presence of higher amount of water may lead to formation of gel. eg; Lutrol F68
Electrical signal sensitive
Hydrogels sensitive to electric current undergo shrinking or swelling in the presence of an applied electric field.
Light-sensitive
Light-sensitive hydrogels can be utilized in the improvement of in situ forming gels for cartilage tissue engineering. eg; Quinone can be injected into a tissue and applied electromagnetic radiation is used to form a gel by enzymatic processes. For that long ultraviolet wavelengths are used forces delivered so as to forestall the disadvantages of unforeseeable intragastric lightness ability varieties 14, 15 .
F = F buoyancy -F gravity = (Df -Ds)gv
Where, F= total vertical force, Df = fluid density, Ds= object density, v= volume, g= acceleration due to gravity 6 Commercial formulations of in-situ gel
Regel depot technology
Regel is one of the Macromed's restrictive medication conveyance framework and dependent on triblock copolymer, 
Cytoryn
This is one of the Macromed's items, which is a novel, 
Pilopine HS
Pilopine HS is a marketed product of Alcon Laboratories Inc.
Pilopine HS (pilocarpinehydrochloride ophthalmic gel) 4% is a sterile topical ophthalmic aqueous gel which containsmore than 90% water and employs Carbopol-940, a synthetic high molecular weight cross-linkedpolymer of acrylic acid, to impart a high viscosity 20 .
Akten™
Akten™ is an HPMC-based gel of lidocaine hydrochloride for 
Virgan
Vigran is an ophthalmic antiviral that is shown for the treatment of intense herpes simplex keratitis. The suggested dosing routine for Virgan is 1 drop in the influenced eye multiple times perday (around at regular intervals while alert) until the corneal ulcer mends, and after that 1 drop 3times every day for 7 days. 
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